ALNOV:EPA
Novacyt SA
0,45 €
arrow_upward
+0,22%(+0,0010) 1D
27 қаз., 17:35:24 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
0,45 €
High
0,46 €
Low
0,44 €
Mkt. cap
31,78 млн
Avg. vol.
195,73 м.
Volume
290,20 м.
52-wk high
1,04 €
52-wk low
0,29 €
EPS
-0,37 €
Shares outstanding
72,59 млн
No. of employees
228
Open
0,45 €
High
0,46 €
Low
0,44 €
Mkt. cap
31,78 млн
Avg. vol.
195,73 м.
Volume
290,20 м.
52-wk high
1,04 €
52-wk low
0,29 €
EPS
-0,37 €
Shares outstanding
72,59 млн
No. of employees
228
News stories
From web sources and news partners
Stocktwits
·
26 минут бұрын
S&P 500, Nasdaq Jump On Chipmaker Strength As Investors Eye October Fed Decision — ORCL, HOOD, JBLU, RIVN, SMCI In Focus
Seeking Alpha
·
43 минут бұрын
Nasdaq Advances For Second Straight Day
조선일보
·
26 минут бұрын
GM Moves to Nasdaq After 115 Years
Reuters
·
5 сағат бұрын
NYSE moves to bring all-or-nothing options to stocks and company earnings
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA